As of April 2025, four CD19-directed chimeric antigen receptor (CAR)-T therapies and three CD20-targeting bispecific antibodies (BsAbs) have been US Food and Drug Administration (FDA) approved for the ...
Bitter taste receptors inside cancer cells have been found to be activated in the presence of anti-cancer drugs. Shutting ...
Chimeric antigen receptor T-cell therapy has exhibited “compelling” efficacy and safety in lupus, allowing 84% of patients to ...
CD19 chimeric antigen receptor T-cell therapy improved lung function and skin thickness in patients with severe refractory systemic sclerosis, with 96% remaining off SSc treatment during follow-up, ...
A research team from the Department of Bioscience, Faculty of Life Sciences, Okayama University of Science, has made a ...
Cancer immunotherapy, especially using T cells, is showing a lot of promise in treating blood cancers. Bioengineered T cells, ...
Study sets stage for development of synthetic biosensors with custom-built sensing and responses for basic and translational cell engineering applications.
A new AI tool that models how variations in peptides change T cell receptor binding could help design immunotherapies with fewer off-target effects. Protein complexes that adorn the surface of T cells ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback